IMVT Stock Up 11% on Upbeat Batoclimab Hyperthyroidism Study ResultsZacks Investment Research • 09/04/25
Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease PatientsGlobeNewsWire • 09/03/25
IMVT Investors Have Opportunity to Join Immunovant, Inc. Fraud Investigation with the Schall Law FirmBusiness Wire • 08/28/25
Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2025GlobeNewsWire • 08/11/25
All You Need to Know About Immunovant (IMVT) Rating Upgrade to BuyZacks Investment Research • 07/16/25
Wall Street Analysts See a 137.68% Upside in Immunovant (IMVT): Can the Stock Really Move This High?Zacks Investment Research • 07/16/25
Immunovant (IMVT) Upgraded to Buy: What Does It Mean for the Stock?Zacks Investment Research • 06/02/25
Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025GlobeNewsWire • 05/29/25
IMVT INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Announces Investigation into a Private Placement Transaction by Immunovant, Inc. and Encourages Investors to Contact the FirmBusiness Wire • 05/22/25
Immunovant Crumbles After Roivant Sweeps Out Its C-Suite, Unveils Strategic ShiftInvestors Business Daily • 04/21/25
Immunovant: TED Data Sets Stage For Batoclimab Regulatory Filings Going ForwardSeeking Alpha • 03/19/25
Roivant, Immunovant Succeed In Phase 3. But There's A Twist — And Shares Tumbled.Investors Business Daily • 03/19/25
Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) StudiesGlobeNewsWire • 03/19/25
Immunovant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) ProgramsGlobeNewsWire • 03/18/25
Immunovant (IMVT) Loses -15.47% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerZacks Investment Research • 02/12/25
FcRn Inhibitor Market Size, Target Population, Competitive Landscape & Forecast to 2034 - Immunovant Advances FcRn Inhibitor Pipeline with Promising Results and FDA Green Light for Pivotal TrialGlobeNewsWire • 12/11/24